πŸ‡ΊπŸ‡Έ FDA
Patent

US 9603853

Formulations of viloxazine

granted A61KA61K31/5375A61K9/00

Quick answer

US patent 9603853 (Formulations of viloxazine) held by Supernus Pharmaceuticals, Inc. expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Supernus Pharmaceuticals, Inc.
Grant date
Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/5375, A61K9/00, A61K9/146, A61K9/2054